Shelley Wood

Shelley Wood is a medical journalist with a focus on cardiology. She has been covering the field for over a decade, providing insights and analysis on the latest developments in cardiovascular medicine.

Biography:  https://www.tctmd.com/author/shelley-wood

96%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

90%

Examples:

  • In the article 'Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials', the author seems to favor the TAVI procedure, but provides balanced information and cites multiple sources.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

100%

Examples:

No current examples available.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

Recent Studies Highlight Effectiveness and Potential Risks of TAVR in Treating Aortic Stenosis

Broke On: Sunday, 01 October 2023 Recent studies have shown that Transcatheter Aortic Valve Replacement (TAVR) is effective in treating aortic stenosis in low-risk patients. The PARTNER 3 and Evolut trials found that TAVR outperformed surgical aortic valve replacement (SAVR) in terms of mortality, stroke, and rehospitalization rates at one year. A separate study found that adding left atrial appendage occlusion (LAAO) to TAVR did not increase the risk of complications.